aTyr Pharma, Inc. - LIFE STOCK NEWS

aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, announced its participation in two investor conferences in March 2023. The first event is the 35th Annual Roth Conference on March 14, 2023, at 10:00 am PDT in Dana Point, CA, featuring a fireside chat. The second is the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:00 am EDT, which will be held virtually as a corporate presentation.

Management will also engage in one-on-one investor meetings. A replay of the corporate presentation will be available on aTyr’s investor website.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced plans to report its fourth quarter and full year 2022 financial results on March 9, 2023, after market close. The company will host a conference call and webcast at 5:00 p.m. EST to discuss these results and provide a corporate update. aTyr focuses on developing first-in-class medicines through its tRNA synthetase biology platform, specifically targeting fibrotic lung disease with its clinical-stage candidate, efzofitimod, which modulates immune responses. This conference is a crucial opportunity for investors to gain insights into the company's operational developments and financial performance.

aTyr Pharma, Inc. (Nasdaq: LIFE) is set to initiate a Phase 2 study for its lead candidate, efzofitimod, targeting systemic sclerosis-associated interstitial lung disease (SSc-ILD) following FDA IND approval. Efzofitimod has been granted both orphan drug and Fast Track designations by the FDA. This study aims to evaluate the safety and efficacy of efzofitimod in 25 patients currently on mycophenolate therapy, with a primary focus on pulmonary and cutaneous manifestations. Preclinical results suggest it effectively reduces fibrosis. There remains a significant unmet need for effective therapies in SSc-ILD, a leading cause of death in scleroderma patients.

aTyr Pharma, a biotherapeutics company, announced the pricing of an underwritten public offering of 22,225,000 shares of common stock at $2.25 per share, expected to generate approximately $50 million in gross proceeds. The offering, closing on February 13, 2023, includes a 30-day option for underwriters to purchase an additional 3,333,750 shares. Proceeds will primarily fund the ongoing development of efzofitimod, particularly a planned Phase 2 study for systemic sclerosis-associated interstitial lung disease.

aTyr Pharma (Nasdaq: LIFE) announced a public offering of its common stock, intending to use proceeds for general corporate purposes and the development of efzofitimod, including a planned Phase 2 study for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in 2023. The offering may include an additional 15% of shares, exercisable by underwriters, and is subject to market conditions. RBC Capital Markets is the sole book-running manager, while H.C. Wainwright & Co. acts as lead manager. The offering is made under a shelf registration statement filed with the SEC.

aTyr Pharma has reached a significant milestone with a $10 million payment from Kyorin Pharmaceutical after the first patient was dosed in Japan for the EFZO-FIT™ Phase 3 study. This pivotal trial evaluates the safety and efficacy of efzofitimod in treating pulmonary sarcoidosis. The $20 million paid to date represents the company’s progression under their collaboration agreement, with potential for up to $155 million more in future milestones. Efzofitimod, an immunomodulator with FDA Fast Track and orphan drug designations, is aimed at patients with limited treatment options, marking a pivotal opportunity for aTyr in the ILD therapeutic space.

aTyr Pharma (Nasdaq: LIFE) announced it will present data on efzofitimod's mechanism of action (MOA) and exposure-efficacy at the ATS 2023 International Conference, May 19-24, in Washington, DC. The presentations highlight advancements in understanding efzofitimod’s clinical benefits for pulmonary sarcoidosis, a serious interstitial lung disease. According to CEO Sanjay S. Shukla, the studies support clinical proof-of-concept, showcasing efzofitimod's modulation of myeloid cells. The presentations include a mini symposium on efzofitimod’s immunological impact and a thematic poster session on exposure-efficacy analysis.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced that the European Patent Office has issued a Notice of Allowance for a patent covering the use of efzofitimod in combination with pirfenidone, an anti-fibrotic drug approved for treating idiopathic pulmonary fibrosis (IPF). This patent strengthens aTyr's position, supporting its ongoing clinical development of efzofitimod, aimed at reducing inflammation and fibrosis in the lungs. The patent grants aTyr over 220 issued or allowed patents, highlighting its leadership in developing first-in-class medicines from its tRNA synthetase platform. The patent is expected to be issued soon.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced the European Commission’s grant of orphan drug designation for efzofitimod, its lead candidate targeting pulmonary sarcoidosis. This designation recognizes the unmet medical need for the estimated 150,000 patients in the EU suffering from this chronic disease. Efzofitimod is a first-in-class immunomodulator designed to improve lung function and quality of life, currently undergoing a pivotal Phase 3 study. This status provides benefits like 10 years of market exclusivity and reduced fees. The drug has also received orphan and Fast Track designations from the FDA in the US.